RxDoctor Payments Data

Gopi Ayer, MD

Internal Medicine · Los Gatos, CANPI 1396701512

Payments from drug & device makers

$1,283in general payments, 2019–2025

Across 64 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$304
  • Novo Nordisk$197
  • GSK$144
  • Medtronic$115
  • Amgen$106
  • Lilly USA, LLC$87
  • plus $330 from 8 others

What the payments were for

  • Food & beverage$1,27199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,283 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$340,699
Medicare patients
547
Services billed
3,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$207,331
XareltoRivaroxaban102$129,859
EliquisApixaban94$125,258
Humira PenAdalimumab13$92,136
JanuviaSitagliptin Phosphate58$74,776
JardianceEmpagliflozin42$63,684
FarxigaDapagliflozin Propanediol32$51,684
MounjaroTirzepatide37$44,524
TrulicityDulaglutide32$40,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$28,450
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$25,945
TradjentaLinagliptin12$18,420
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide327$12,196
Atorvastatin Calcium810$8,664
Tresiba Flextouch U-100Insulin Degludec11$5,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$207,331122 claims
Johnson & JohnsonXarelto$18$129,859102 claims
PfizerEliquis$304$125,25894 claims
Lilly USA, LLCMounjaro, Trulicity$87$84,53369 claims
MerckJanuvia$35$74,77658 claims
AstraZenecaFarxiga$80$51,68432 claims
GSKTrelegy Ellipta$144$28,45046 claims
AbbVieSynthroid$41$4,25035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →